Atrial Fibrillation Paroxysmal Clinical Trial
— SOLUTIONOfficial title:
ASsessment Of RiLuzole To Reduce Paroxysmal Episodes of Atrial FIbrillatiON (The SOLUTION Study)
Atrial fibrillation (AF) is a growing clinical problem.1 AF is a highly dynamic condition involving episodes of sinus rhythm interspersed with periods of arrhythmia, becoming more difficult to terminate over time. AF carries a substantial cost, morbidity and mortality burden. There are two important approaches to the management of AF: 1). Controlling ventricular response rate without attempting to terminate or prevent AF (rate control), and 2). Attempting to control and maintain sinus rhythm (rhythm control).2 Current rhythm control with antiarrhythmic agents (AAD) is only moderately beneficial in restoration and maintenance of sinus rhythm but produce serious adverse events. AAD selection is limited based on the potential for pro-arrhythmia, patient's age, presence of structural heart disease, and renal or hepatic dysfunction. All AF anti-arrhythmic agents are associated with harm (number needed to harm 17-119).3 There remains an important need for development of an efficacious safe AAD for the control of AF. Recent published translational studies suggest that that neuronal-type Na+ channel blockade (nNav) with riluzole, a nNav inhibitor used to manage amyotrophic lateral sclerosis (ALS), can effectively suppress triggered atrial arrhythmias.4 In two independent retrospective cohorts, riluzole-treated ALS patients significantly lowered the incidence of new-onset AF. Riluzole is well-tolerated without evidence of pro-arrhythmia.5 Therefore, to assess riluzole's effects on the reduction of paroxysmal episodes of AF, we will conduct a prospective, randomized, placebo-controlled human study using holter monitors that offer continuous electrocardiographic monitoring pre- (1 month) and with exposure to riluzole or placebo (1 month) to determine statistically superior reductions in episodes of AF.
Status | Recruiting |
Enrollment | 78 |
Est. completion date | October 30, 2024 |
Est. primary completion date | October 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males or Female adult patients (> 18 years old) with a history of symptomatic AF documented electrocardiographically within > 48 hours to 12 months before enrollment. - Is able to provide written informed consent to participate in the study and is able to understand the procedures and study requirements. - Must voluntarily sign and date an informed consent form that approved by the University of Utah IRB before the conduct of any study-specific procedure. - Will be anti-coagulated or is already anti-coagulated for planned cardioversion. - Is planned to undergo a cardioversion. - Patients who are not being treated with an anti-arrhythmic agent per their physician's treatment plan Exclusion Criteria: - Systolic BP > 180 mmHg or Diastolic BP > 100 mmHg; - Atrial Fibrillation due to electrolyte imbalance, hyperthyroidism, pericarditis, or other reversible illness; - NYHA FC IV Heart Failure (No ADHF Decompensation with 1 month); - Unstable Angina, AMI, coronary surgery within 3 or coronary angioplasty within 1 month of screening; - Wolff-Parkinson-White syndrome unless treated with successful ablation; - Infiltrative heart disease; - Severe valvular heart disease; - History of syncope or angina precipitated by an ventricular arrhythmia; - History of torsade de pointes; - Any polymorphic ventricular tachycardia; - Sustained monomorphic ventricular tachycardia, or cardia arrest; - Class I or III antiarrhythmic agents; - Females of childbearing age. If female, is either not of childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy, or hysterectomy]) or is practicing 1 of the following medically acceptable methods of birth control for at least one full menstrual cycle prior to screening (see below), and agrees to continue with the regimen from the time of screening, throughout the entire study they are excluded; - Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives for a minimum of 3 full cycles (based on the subject's usual menstrual cycle period) before study medication administration - Total abstinence from sexual intercourse since the last menses before study medication administration - Intrauterine device - Double-barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream); - Aminotransferases > 5 x ULN (Test in the last 3 months); - CYP 1A2 Potent Inhibitors including cimetidine, ciprofloxacin, enoxacin, rifampin, barbiturates, and fluvoxamine; and - Active tobacco use. (i.e., smoking) |
Country | Name | City | State |
---|---|---|---|
United States | University of Utah | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
University of Utah | Ohio State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Episodes of Tachycardia | Number of episodes of atrial fibrillation in 1 month between riluzole 50mg BID versus matching placebo; | 30 Days | |
Primary | Time to First Tachycardia Episode | Time to first episode of atrial fibrillation between riluzole 50mg BID and placebo | 30 Days | |
Secondary | Safety of Riluzole Pro-Arrhythmia | 1. Pro-arrhythmia measured as number of episodes of V tachycardia over 30 days | 30 Days | |
Secondary | Safety of Riluzole Neutropenia | Neutropenia measured by change on CBC [baseline and 1-month end] and patient signs and symptoms [weekly phone call F/U]). | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06085014 -
Clinical and Electrophysiological Predictors of Arrhythmic Recurrence in Patients With Paroxysmal AF Undergoing First Ablation Procedure of AF by Pulmonary Vein Isolation
|
||
Recruiting |
NCT03724383 -
Atrial Fibrillation Lifestyle Project
|
N/A | |
Active, not recruiting |
NCT04544397 -
Outcomes of Second Generation Laser Balloon Ablation for Atrial Fibrillation
|
||
Not yet recruiting |
NCT05940597 -
Pulsed Field Ablation vs Cryoablation In Paroxysmal Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT04447300 -
Outcomes of High Power Application in Catheter Ablation of Paroxysmal Atrial Fibrillation Guided by Unipolar Signal Modification.
|
N/A | |
Recruiting |
NCT05251545 -
Randomized Trial: High Power Short Duration Versus Ablation Index
|
N/A | |
Recruiting |
NCT05883631 -
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
|
N/A | |
Not yet recruiting |
NCT04600713 -
Physiotherapist-led Exercise Within Cardiac Rehabilitation and Paroxysmal Atrial Fibrillation and COVID-19.
|
N/A | |
Enrolling by invitation |
NCT05725187 -
Prospective Validation Study of AI-based Prediction Algorithm for the Prediction of Paroxysmal Atrial Fibrillation
|
||
Recruiting |
NCT04606693 -
Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates
|
N/A | |
Recruiting |
NCT05328882 -
Early Recurrences of Atrial Arrhythmias and Their Impact on Late Recurrence After Pulmonary Vein Isolation With Pulsed Field Ablation of Paroxysmal Atrial Fibrillation
|
||
Recruiting |
NCT04342312 -
Intensive Molecular and Electropathological Characterization of Patients Undergoing Atrial Fibrillation Ablation
|
||
Recruiting |
NCT05549752 -
Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia
|
Phase 3 | |
Completed |
NCT03323099 -
Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation
|
N/A | |
Completed |
NCT05461859 -
Cardioneuroablation for the Treatment of Vagally-mediated Atrial Fibrillation.
|
||
Enrolling by invitation |
NCT04634461 -
The Relationship Between Panic Attack Symptoms and Atrial Fibrillation Episodes.
|
||
Completed |
NCT04023461 -
Isolation of Pulmonary Veins With PVAC GOLD in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT06392932 -
Esophageal Temperature During PVI Using Q-DOT Micro
|
N/A | |
Not yet recruiting |
NCT06364215 -
Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
|
N/A | |
Completed |
NCT04511520 -
Efficacy of Personalized Exercise Program and Trimetazidine in Rehabilitation of Patients After RFA of AF
|
N/A |